Last reviewed · How we verify
Administration of Ivermectin on Day 1
At a glance
| Generic name | Administration of Ivermectin on Day 1 |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC) (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Ivermectin Repurposed for the Treatment of PKDL (EARLY_PHASE1)
- Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer (PHASE1, PHASE2)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness (PHASE3)
- Repurposing Ivermectin for PKDL Treatment (EARLY_PHASE1)
- Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: